Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients (SONOKID)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05293197 |
|
Recruitment Status :
Recruiting
First Posted : March 24, 2022
Last Update Posted : February 21, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Purpose : the aim of this study is to assess the feasibility and safety of ultrasound-induced opening of the blood-brain barrier (BBB) with the SonoCloud-9 implantable ultrasound device in pediatric patients treated for a recurrent malignant supra-tentorial brain tumor treated with carboplatin.
Study hypothesis : the blood-brain barrier can be transiently and safely opened with pulsed low intensity ultrasound immediately prior to intravenously delivered chemotherapy. The opening of the BBB with the SonoCloud-9 system will increase the tumor exposure to carboplatin and increase progression-free and overall survival in pediatric patients treated for a recurrent malignant supra-tentorial brain tumor.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Malignant Brain Tumor Malignant Glioma Embryonal Tumor | Device: SonoCloud® (9 transducers) | Phase 1 |
Malignant brain tumors are the first cause of death by cancer in children and adolescents. The dismal prognosis of malignant brain tumors is partially due to the existence of the blood brain barrier (BBB), a physiological barrier that limits the penetration of almost all molecules from the blood stream to the brain, including antineoplastic drugs.
It has been shown that the application of low intensity ultrasound on the brain in association with intravenous microbubbles leads to transient and safe opening of the BBB. Many preclinical studies have demonstrated that ultrasound-induced opening of the BBB increases the distribution of therapeutic molecules into the brain and allows tumor control and increases survival in animal models (mice, rabbits, pigs, primates).
An innovative implantable ultrasound system, the SonoCloud device, has been developed in order to repeatedly open the BBB in synchronization with chemotherapy protocols.
This intracranial and subcutaneous device is not visible and MRI compatible and allows repeatable and ambulatory treatments. Moreover, such a device allows the delivery of low intensity ultrasound in a controlled and reproductible manner.
A phase I/IIa trial has confirmed the feasibility and safety of this technique in adult patients treated for recurrent glioblastoma with carboplatin-based chemotherapy.
This study will assess the feasibility and safety of ultrasound-induced opening of the BBB with the SonoCloud device in pediatric patients treated with carboplatin chemotherapy for a recurrent supra-tentorial malignant brain tumor. The study will determine the maximum tolerated ultrasound acoustic pressure that can be used for BBB opening and the safety of the activation of 3, then 9 transducers with the SonoCloud-9® device. Patients will follow 6 months cycles of treatment. If the treatment is well tolerated, patients will be able to be treated for 6 more cycles.
The magnitude and intensity of the BBB opening, its clinical (overall survival) and radiological (progression-free survival) efficacy will be assessed as secondary endpoints. Safety of the ultrasound contrast agent SonoVue will also be evaluated in this indication in the pediatric population.
An ancillary study will assess circulating tumor DNA (ctDNA) concentrations in patients with recurrence of a supra-tentorial malignant brain tumor, at diagnosis and during repeated opening of the BBB. The study will assess the correlation between ctDNA concentrations and tumor evolution.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 24 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Phase I Trial Assessing the Safety of the Repeated Ultrasound-induced Opening of the Blood-brain Barrier in Pediatric Patients With Refractory Supra-tentorial Malignant Brain Tumors Before Chemotherapy Administration |
| Actual Study Start Date : | February 6, 2023 |
| Estimated Primary Completion Date : | October 2026 |
| Estimated Study Completion Date : | October 2026 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: SonoCloud®
SonoCloud® : dose escalation 6 cycles of sonication
|
Device: SonoCloud® (9 transducers)
SonoCloud®, sonication: dose escalation 6 cycles of sonication |
- Dose limiting toxicity directly linked to US emissions by the SonoCloud-9® (3 transducers) [ Time Frame: Monthly up to 12 months ]Clinical evaluation (neurological deficit, intracranial hypertension, epilepsy) during acoustic pressure dose escalation, after each sonication (48h)
- Dose limiting toxicity directly linked to US emissions by the SonoCloud-9®(3 transducers) [ Time Frame: Monthly up to 12 months ]Radiological evaluation (hemorrage, ischemia, brain swelling) during acoustic pressure dose escalation, after each sonication
- BBB opening intensity with the SonoCloud® device [ Time Frame: Monthly, up to 12 months ]Grading of BBB disruption using the scale previously described (Carpentier et al 2016), after each sonication
- Clinical efficacy of BBB disruption by the SonoCloud® device in association with systemic chemotherapy [ Time Frame: Month 3 ]Overall Survival (OS)
- Clinical efficacy of BBB disruption by the SonoCloud® device in association with systemic chemotherapy [ Time Frame: Month 6 ]Overall Survival (OS)
- Radiological efficacy of BBB disruption by the SonoCloud® device in association with systemic chemotherapy [ Time Frame: Month 3 ]Progression Free Survival (PFS) using RANO Criteria
- Radiological efficacy of BBB disruption by the SonoCloud® device in association with systemic chemotherapy [ Time Frame: Month 6 ]Progression Free Survival (PFS) using RANO Criteria
- Allergic adverse events related to ultrasound contrast agent SonoVue® [ Time Frame: Monthly, up to 12 months ]Allergic reactions (cutaneous eruption, oedema, respiratory failure) in relation to the use of the ultrasound contrast agent SonoVue® for BBB disruption in the pediatric population, during and after each sonication
- Cardiac adverse events related to ultrasound contrast agent SonoVue® [ Time Frame: Monthly, up to 12 months ]Cardiac reactions (thoracic pain, cardiac failure, EKG modification) in relation with the use of the ultrasound contrast agent SonoVue® for BBB disruption in the pediatric population, during and after each sonication
- Feasibility of the BBB disruption technique [ Time Frame: Monthly, up to 12 months ]Complications associated with the implantation of the SonoCloud® device : acute pain evaluation using VAS (Visual Analogue Scale) for patients >_ 7 years old or using behavioral pain scale EVENDOL for patients <7 years old, immediately after implantation
- Feasibility of the BBB disruption technique [ Time Frame: Monthly, up to 12 months ]Complications associated with the implantation of the SonoCloud® device : acute pain evaluation using VAS (Visual Analogue Scale) for patients >_ 7 years old or using behavioral pain scale EVENDOL for patients <7 years old, at day 1 after implantation
- Feasibility of the BBB disruption technique [ Time Frame: Monthly, up to 12 months ]Complications associated with the implantation of the SonoCloud® device : chronic pain evaluation using VAS (Visual Analogue Scale) for patients >_7 years old or using behavioral pain scale EVENDOL for patients <7 years old, monthly, before each new cycle of treatment
- Feasibility of the BBB disruption technique [ Time Frame: Day 1 after implantation ]Complications associated with the implantation of the SonoCloud® device using radiological examination : device position and post-operative complication (hematoma), one day after implantation
- Feasibility of the BBB disruption procedure [ Time Frame: Monthly, up to 12 months ]Assessment of complications associated with the sonications : pain evaluation using VAS (Visual Analogue Scale) for patients >_ 7 years old or using behavioral pain scale EVENDOL for patients <7 years old at needle connexion
- Feasibility of the BBB disruption procedure [ Time Frame: Monthly, up to 12 months ]Complications associated with the implantation of the SonoCloud® device : pain evaluation using VAS (Visual Analogue Scale) for patients >_ 7 years old or using behavioral pain scale EVENDOL for patients <7 years old, during sonication
- Skin complications relation to the BBB disruption procedure [ Time Frame: Monthly, up to 12 months ]Assessment of skin complications associated with sonications : eschar and/or infection, before each cycle of treatment
- Feasibility of the BBB disruption procedure [ Time Frame: Monthly, up to 12 months ]Process evaluated by the surgeon: number of tests necessary for needle connexion to the device, at each sonication
- Feasibility of the BBB disruption procedure [ Time Frame: Monthly, up to 12 months ]Process evaluated by the surgeon : duration from needle connexion to the end of sonication, at each sonication
- Feasibility of the BBB disruption procedure [ Time Frame: During surgery ]Process evaluated by the surgeon : duration for device implantation
- Biodisponibility of the SonoCloud-9® device [ Time Frame: 12 months ]Histological analysis of tissue around the device : thickness, inflammation, biocompatibility, at explantation
- Assessment of SonoCLOUD- 9® device resistance [ Time Frame: 12 months ]Physical analysis of the device, at explantation
- DNA and tumor cells concentrations in blood and cerebrospinal fluid [ Time Frame: Monthly, up to 12 months ]Evaluation of the effect of BBB disruption with the SonoCloud-9® device on the circulation of tumoral components in the blood flow, at each cycle of treatment
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 5 Years to 17 Years (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- patient aged ≥ 5 years old and < 18 years old
- patient able to receive sonications and perform MRI studies without sedation
- diagnosis of supra-tentorial primary malignant brain tumor (e.g. malignant glioma, embryonal tumor including ATRT, ependymoma)
- recurrence or progression of brain tumor after at least a first line of standard treatment (multifocal tumors and metastatic disease allowed)
- indication of treatment with carboplatin, validated in multidisciplinary meeting
- Karnofsky performance scale index (patients ≥ 16 years old) or Lansky performance status (patients < 16 years old) > 50% (a patient with a performance status score altered by a motor deficit due to tumor infiltration will be allowed to be included)
- no threat of brain herniation or uncontrolled intracranial hypertension
- corticosteroids treatment ≤ 1mg/kg/day
- neutrophils > 1.5 x 109/L
- platelets > 100 x 109/L
- total bilirubin < 1.5x upper limit of normal, AST et ALT < 2.5x upper limit of normal
- serum creatinin < 1.5x upper limit of normal for the age or creatinine clairance >70mL/min/1.73m2 (EDTA method or 24h urine)
- coagulation parameters in the normal limits for age (fibrinogen, prothrombin time and activated clotting time)
- no grade 2 or more toxicity depending on the NCI-CTCAE v5.0 criteria
- no healed wound on the scalp
- covered by health insurance
- for patients of chilbearing age (15-17 years old) : a negative pregnancy test and an efficient method of birth control
- written consent signed by the patient (if possible) and his parents or legal representatives.
Exclusion Criteria:
- weight <10kg
- significant intra-tumoral bleeding (hematoma) or ipsilateral subdural effusion
-
antineoplastic treatment other than carboplatin taken at the same time or stopped since less than:
- 6 weeks for nitrosoureas
- 1 month for temozolomide
- 1 month for bevacizumab
- 5 half-lives for tyrosin kinase inhibitors
- 3 weeks for any other chemotherapy
for the first sonication session
- radiotherapy during the last 6 weeks
- any other cancer treated during the last 5 years
- any other uncontrolled disease or active infection
- any other co-morbidity that could compromise participation to the study (in the judgement of the clinical investigator)
- any anatomical particularity (skull thickness, thin skin) that could compromise a safe implantation of the device and/or compromise the quality of the treatment (in the judgement of the clinical investigator)
- implanted defibrillator/pacemaker, neurostimulator, cochlear implant, intracerebral ferromagnetic vascular clip
- any contraindication to general anesthesia
- any contraindication to MRI or known allergy to gadolinium or other MRI contrast agent/
-
any contraindication to ultrasound contrast agent:
- allergy to the active substance or any excipient
- acute coronary syndrome or uncontrolled ischemic heart disease
- chronic heart failure or history of acute heart failure or heart failure grade III or IV
- treatment with dobutamine
- severe pulmonary arterial hypertension
- uncontrolled systemic hypertension
- respiratory distress syndrome
- carboplartin hypersensitivity
- treatment with phenytoin or fosphenytoin
- earlier vaccination with attenuated alive vaccine
- diminished auditory acuity ≥ grade 3 on CTCAE classification
- history of thermoregulation disorder
- impossibility of a rigorous medical follow-up due to geographic, social or mental reasons
- pregnant and lactating women
- contemporaneous treatment by anticoagulant or platelet aggregation inhibiting drugs
-
contemporaneous treatment possibly toxic for the central nervous system. The following treatments are excluded if taken less than 5 half-lives before the ultrasound session (unknown toxicity in case of BBB disruption) :
- benzodiazepine (or any sedative or hypnotique drug)
- antihistamine
- proconvulsant drugs
- butyrophenone, phenothiazine, or any "conventional" antipsychotic drug
- barbiturate
- MAO inhibitor
- anticholinergic
- anticoagulant
- any contemporaneous treatment that, in the judgement of the clinical investigator, could induce brain toxicity after BBB disruption
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05293197
| Contact: Kevin BECCARIA, MD, PhD | +33 1 71 39 65 92 | kevin.beccaria@aphp.fr | |
| Contact: Nelly BRIAND, MD, PhD | +33 1 44 38 18 62 | nelly.briand@aphp.fr |
| France | |
| Institut Curie | Recruiting |
| Paris, France, 75005 | |
| Contact: Franck BOURDEAUT, MD, PhD +33 1 4432 44 71 franck.bourdeaut@curie.fr | |
| Principal Investigator: Franck BOURDEAUT | |
| Service de neurochirugie Pédiatrique - Hôpital Necker- Enfants Malades | Recruiting |
| Paris, France, 75015 | |
| Contact: Kevin BECCARIA, MD, PhD +33 1 71 39 65 92 kevin.beccaria@aphp.fr | |
| Principal Investigator: Kevin BECCARIA | |
| Institut Gustave Roussy | Recruiting |
| Villejuif, France, 94800 | |
| Contact: Jacques GRILL, MD, PhD +33 142116209 jacques.grill@gustaveroussy.fr | |
| Principal Investigator: Jacques GRILL | |
| Principal Investigator: | Kevin BECCARIA, MD, PhD | Assistance Publique - Hôpitaux de Paris |
Publications:
| Responsible Party: | Assistance Publique - Hôpitaux de Paris |
| ClinicalTrials.gov Identifier: | NCT05293197 |
| Other Study ID Numbers: |
D20181321 2021-002790-26 ( EudraCT Number ) |
| First Posted: | March 24, 2022 Key Record Dates |
| Last Update Posted: | February 21, 2023 |
| Last Verified: | February 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Low intensity pulsed ultrasound (LIPU) Therapeutic ultrasound Blood-brain barrier (BBB) Malignant brain tumor |
Brain cancer Carboplatin Children Adolescents |
|
Neoplasms Brain Neoplasms Glioma Central Nervous System Neoplasms Nervous System Neoplasms Neoplasms by Site Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue |